We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+2.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.4B
AUM Growth
+$1.55B
(+3.4%)
Cap. Flow
-$454M
Cap. Flow
% of AUM
-0.96%
Top 10 Holdings %
Top 10 Hldgs %
21.97%
Holding
1,164
New
118
Increased
281
Reduced
356
Closed
129
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$485M |
| 2 |
Signet Jewelers
SIG
|
+$418M |
| 3 |
Skyworks Solutions
SWKS
|
+$325M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$324M |
| 5 |
Crown Holdings
CCK
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$321M |
| 2 |
GXP
Great Plains Energy Incorporated
GXP
|
+$299M |
| 3 |
HMHC
Houghton Mifflin Harcourt Company
HMHC
|
+$198M |
| 4 |
Pfizer
PFE
|
+$171M |
| 5 |
K
Kellanova
K
|
+$165M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 15.61% |
| 2 | Healthcare | 15.04% |
| 3 | Technology | 12.55% |
| 4 | Industrials | 12.54% |
| 5 | Financials | 11.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Workday
WDAY
$41.5B
| $3.23M | 0.01% |
43,300
-4,780
| -10% | -$364K |
|
477
TripAdvisor
TRIP
$1.7B
| $3.22M | 0.01% |
50,085
| – | – |
|
478
Azenta
AZTA
$1.3B
| $3.21M | 0.01% |
+286,472
| New | +$3M |
|
479
Ternium
TX
$9.43B
| $3.19M | 0.01% |
+167,405
| New | +$3.17M |
|
|
DPLO
480
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $3.18M | 0.01% |
90,900
| – | – |
|
481
Mitsubishi UFJ Financial
MUFG
$247B
| $3.16M | 0.01% |
712,600
| – | – |
|
|
ETW
482
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund
ETW
$1.01B
| $3.15M | 0.01% |
303,293
-22,000
| -7% | -$231K |
|
483
Boeing
BA
$169B
| $3.15M | 0.01% |
24,234
+21,205
| +700% | +$2.76M |
|
484
Northrop Grumman
NOC
$76B
| $3.14M | 0.01% |
14,121
+1,033
| +8% | +$217K |
|
|
MKTO
485
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $3.13M | 0.01% |
89,925
-37,800
| -30% | -$1.05M |
|
|
TIME
486
DELISTED
Time Inc.
TIME
| $3.11M | 0.01% |
189,178
+10,395
| +6% | +$161K |
|
487
Neurocrine Biosciences
NBIX
$18.2B
| $3.08M | 0.01% |
+67,684
| New | +$3.12M |
|
488
iShares MSCI EAFE ETF
EFA
$76.4B
| $3.05M | 0.01% |
54,699
-1,763
| -3% | -$101K |
|
489
Penumbra
PEN
$12.6B
| $3.03M | 0.01% |
50,975
-12,000
| -19% | -$647K |
|
|
ROIC
490
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $2.96M | 0.01% |
136,804
+31,786
| +30% | +$643K |
|
491
Welltower
WELL
$173B
| $2.96M | 0.01% |
38,845
-2,293
| -6% | -$163K |
|
|
FISV
492
Fiserv Inc
FISV
$29.7B
| $2.93M | 0.01% |
53,860
-57,014
| -51% | -$2.93M |
|
493
Supernus Pharmaceuticals
SUPN
$2.7B
| $2.92M | 0.01% |
+143,300
| New | +$2.54M |
|
|
CSRA
494
DELISTED
CSRA Inc.
CSRA
| $2.91M | 0.01% |
124,350
-226,000
| -65% | -$5.68M |
|
|
DATA
495
DELISTED
Tableau Software, Inc.
DATA
| $2.88M | 0.01% |
58,900
-1,800
| -3% | -$90.2K |
|
496
Standard BioTools
LAB
$342M
| $2.87M | 0.01% |
318,175
-71,800
| -18% | -$675K |
|
|
GGP
497
DELISTED
GGP Inc.
GGP
| $2.87M | 0.01% |
96,299
+28,059
| +41% | +$792K |
|
498
Equity Residential
EQR
$25.8B
| $2.87M | 0.01% |
41,599
+39,831
| +2,253% | +$2.74M |
|
|
LLTC
499
DELISTED
Linear Technology Corp
LLTC
| $2.78M | 0.01% |
59,758
+59,633
| +47,706% | +$2.73M |
|
500
BioMarin Pharmaceuticals
BMRN
$11.9B
| $2.77M | 0.01% |
+35,619
| New | +$3.03M |
|
Similar funds
QCM
Lazard Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Lazard Asset Management held 1,164 positions worth $47.4B, up 3.4% from $45.8B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Lazard Asset Management's Q2 2016 filing shows 118 new, 281 increased, 356 reduced and 129 closed positions. Its largest new stake was Crown Holdings: 5,754,541 shares worth $292M. The largest sale was Apple, an estimated $321M.
By sector, the portfolio is most concentrated in Communication Services at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Technology.
- Lazard Asset Management's largest Q2 2016 buy was Crown Holdings: 5,754,541 shares worth $292M.
- Lazard Asset Management added most to Allergan plc in Q2 2016, an estimated $485M increase.
- Lazard Asset Management's biggest Q2 2016 reduction was Apple, cutting an estimated $321M.
- Lazard Asset Management fully exited APA Corp in Q2 2016, selling an estimated $65M.
- Lazard Asset Management's ten largest holdings make up 22% of its $47.4B portfolio in Q2 2016.
- Lazard Asset Management opened 118 new positions and closed 129 in Q2 2016.
- Lazard Asset Management's portfolio value rose 3.4% quarter-over-quarter to $47.4B.
Based on Lazard Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.